Anyone try LDN

carmen07
carmen07 Member Posts: 120 Member
edited March 2014 in Lung Cancer #1
Hi Everyone,
My sister in law was diagnosed with Stage 4 cancer that met to brain and bone. Has anyone on the board tried LDN for treatment.
She had radiation treatments and met with oncologist that gave her a poor prognosis. About 4 months with treatment.
Also anyone on the board that did not test for the mutation of tarceva that did well. I know I read about someone with stage 4. Any help I would appreciate.

Comments

  • HeartofSoul
    HeartofSoul Member Posts: 729 Member
    #2
    below is for MS and
    below is for MS and fibromyalgia in trial. i doubt anyone here has heard of LDN but it entails the use of methods that are not scientifically accepted. you will find site that promote LDN for all kinds of ailments but first read link

    http://www.quackwatch.org/01QuackeryRelatedTopics/quacksell.html


    Low Dose Naltrexone for the Treatment of Fibromyalgia

    Dr. Jarred Younger, PhD and Dr. Sean Mackey, MD, PhD, of the Stanford Systems Neuroscience and Pain Lab are currently enrolling patients for a clinical trial investigating low-dose naltrexone for the treatment of fibromyalgia. There are no pharmaceutical industry or business interests involved in this study.

    http://snapl.stanford.edu/ldn/



    http://www.unitedspinal.org/publications/action/2008/02/25/multicenter-clinical-trials-of-ldn-for-ms/

    Italian Study
    A long-awaited pilot study of LDN therapy in MS has been implemented by the Milan neurological researcher, Dr. Maira Gironi. Dr. Gironi’s research team has long been a locus for significant research on endorphins in relation to illness, and this study will track accurate assessments of the patients’ beta-endorphin levels in response to their LDN treatment.

    This will be a 6-month pilot, multicentric, open-label, therapeutic study of 40 patients with Primary Progressive MS between the age of 18 and 60. The subjects are over 3 and less than 6 on the expanded disability severity scale (EDSS). They are affected with spasticity, pain, and/or fatigue. Optimization of gabaergic or serotoninergic drugs before entering the study was requested. Any opioid-containing drug, immunosuppressive or immunomodulator medicines were not allowed. All 40 patients are being treated with LDN at a final dose of 5 mg after a 2-week titration of 2.5 mg.

Discussion Boards